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osteopontin   (OPN),   bone   sialoprotein   (BSP),   dentin   sialophosphoprotein   (DSPP),   dentin 
matrix protein­1 (DMP­1) and matrix extracellular glycohosphoprotein (MEPE).  The genes 
for this family are aligned on a portion of human chromosome 4 (mouse chromosome 5), 
within a  «  Bone Gene Cluster  »   [2,  3]  grouping other  genes  of  bone  interest.  Molecular 
evolution  studies   [4,  5]  suggest   that  SIBLINGs,  along with enamelins  and other  proteins 
found   in   milk   (caseins)   and   saliva   (statherin),   form   a  «  Secretory   Calcium   binding 
PhosphoProteins  » (SCPP) family  [4], sharing as a common ancestor Hevin [6], and more 
precisely the long N­terminal domain that distinguishes it from the related protein SPARC 
(secreted  protein,   acidic   and   rich   in   cystein)/Osteonectin   [7].  The  SCPP share   a   flexible 
structure,  and many contain numerous acidic aminoacid residues, which favor interactions 
with crystals   (review in [8]).  The SIBLINGs,  more  specifically,  have acidic  pI   (with   the 
exception of MEPE), and display in their sequence a proline­rich stretch (basic), consensus 
sites for casein­kinase, an arginine­glycine­aspartic acid (RGD) sequence binding intergrin 








present   in  multiple   non­mineralized   tissues,   expecially  with   secretory   functions   (salivary 
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(a  powerful  negative  regulator  of phosphatemia  [16])  as well  as  MEPE [17].   In contrast, 
MEPE   knockout   increases   bone  mass   [18].  A  major   inhibitory   factor   of  mineralisation 
(“Minhibin”, [19]) is the ASARM peptide (review in [9]), which is cleaved by cathepsins B 
and K from MEPE and DMP­1, circulates in blood and is responsible for the high levels of 
osteomalacia  observed   in   hypophosphatemia   [10].  The  most   studied  of  SIBLINGs,  OPN 
(review   in   [20]),   is   a   ubiquitous   protein  whose   functions   range   from   inflammation   to 
lactation, and which has been called a cytokine [21]. The bones of OPN knockout mice [22] 




CD44,  OPN  thus   appears   directly   involved   in   the   regulation   of   cell   adhesion   and   bone 
remodeling.  Interestingly,  OPN ­/­ bone is also hypermineralized,  and lack of OPN partly 
compensates osteomalacia in mice with a knockout of tissue non specific alkaline phosphatase 
(TNALP),  confirming   that  OPN also  plays  a  part  as  a  physiological   inhibitor  of  organic 
matrix mineralization [25]. Considering that OPN and BSP (review in [26]) are the two major 
SIBLINGs expressed in bone forming osteoblasts, it is important to clarify the specificities 
4
and redundancies in their respective functions.
The roles of BSP ­ insights from a mild phenotype knockout
We generated BSP knockout (BSP-/-) mice through genetic recombination, and studied both 
their basal phenotype and their response to challenges [27]. BSP-/- mice develop and grow 
normally, but remain smaller than their wild-type counterparts throughout life (Figure 1a, b). 
Cortical bone is thinner in young mutant mice (Figure 1c) and progressively increases with 
age to reach wild type  values.  BSP-/-  mice display early,  mild matrix  hypomineralization 
(~5% in adults), which also progressively normalizes in older mice.  Previous  in vitro  data 








type   I   collagen,   indicating   that,   beyond   crystal   nucleation,   lack   of   BSP   also   affects 
mineralization   through   alterations   of   the   osteoblast   phenotype   and   matrix 
amount/composition. This confirms previous work with recombinant proteins, showing the 
importance   of   BSP,   specifically   the  RGD   containing   portion,   for   osteoblast   phenotypic 
regulation [32]. Osteoblast phenotype impairment could also explain why the bone formation 





microtomography.   The   lack   of   BSP   significantly   delayed   the   filling   up   of   the   defect 
respective to wild­type controls, confirming the impairment of bone formation (data to be 
published). Surprisingly with such low BFR, trabecular bone volume is higher (~30%) in 4 
month  old  BSP­/­   long  bones   than   in  wild   type   (Figure  1c),   indicating   a   concommitant 
reduction of bone resorption. Osteoclast surfaces and numbers are indeed reduced in mutant 
mice (Figure 1d), and impaired osteoclast differentiation from BSP­/­ spleen and marrow cells 
was confirmed in vitro  [27], in accordance with previous studies [33, 34].  We then asked 






a   high   trabecular   bone  mass  with   low  bone   turnover   that   is,   nonetheless,   responsive   to 
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from +/+   and   ­/­  mice   ;   (d)   quantification  of   bone   formation   rate   (BFR)   and  osteoclast 
surfaces (Oc.S/BS) in the tibial trabecular bone of +/+ and ­/­ mice ; (e) 3D microtomographic 
reconstruction of trabecular bone in the metaphysis of  +/+ and ­/­ femurs. The original data 
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